Company Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1.
The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors.
In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
| Country | Netherlands |
| Founded | 2003 |
| IPO Date | May 19, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 321 |
| CEO | Sven Lundberg |
Contact Details
Address: Uppsalalaan 17, 3rd & 4th floor Utrecht, 3584 CT Netherlands | |
| Phone | 31 30 253 8800 |
| Website | merus.nl |
Stock Details
| Ticker Symbol | MRUS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001651311 |
| CUSIP Number | N5749R100 |
| ISIN Number | NL0011606264 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sven Ante Lundberg M.D. | Chief Executive Officer, President and Executive Director |
| Gregory D. Perry | Chief Financial Officer |
| Peter B. Silverman J.D. | EVice President, Company Secretary, Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal |
| Dr. Hennie Hoogenboom | Co-Founder and Scientific Advisor |
| Harry Shuman | Chief Accounting Officer |
| Cornelis Adriaan de Kruif Ph.D. | Chief Technology Officer and Executive Vice President |
| Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. | Chief Scientific Officer and Senior Vice President |
| Kathleen Farren | IR and Corporate Communications Officer |
| Audrey Bergan | Chief People Officer |
| Shannon Campbell | Executive Vice President and Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 10, 2025 | SCHEDULE 13G | Filing |
| Dec 16, 2024 | SCHEDULE 13G | Filing |
| Dec 5, 2024 | 8-K | Current Report |
| Dec 2, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |